ISA101

Ma W, Melief CJ, van der Burg SH. “Control of immune escaped human papilloma virus is regained after therapeutic vaccination.” Curr Opin Virol. 2017 Apr;23:16-22.

Welters MJ, van der Sluis TC, van Meir H, et. al., Melief CJ, van der Burg SH. “Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.” Sci Transl Med. 2016 Apr 13;8(334):334ra52

van Poelgeest MI, et al., Melief CJ, van der Burg SH. “Vaccination against oncoproteins of HPV16 for non-invasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response.” Clin Cancer Res 2016 May 15;22(10):2342-50

Van der Sluis TC, van der Burg SH, Melief CJ. “Synergy between chemotherapy and cancer vaccination.” Aging 2015 Jun;7(6):340-1

Van der Sluis TC, et al., Melief CJ. “New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer.” Curr Opin Immunol. 2015 May 19. 35: 9-14

Van der Sluis TC, et al., Melief CJ. “Vaccine-induced Tumor Necrosis Factor producing T-cells synergize with cisplatin to promote tumor cell death.Clin Cancer Res. 2015 21(4): 781-794

De Vos van Steenwijk PJ, et al., Melief CJ, Welters MJ, van der Burg SH, Kenter GG. “The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine vervix: a placebo-controlled phase II study.” Cancer Immunol Immunother. 2014 Feb. 63(2): 147-160

CJ Melief et al. “Prior chemotherapy improves the immune response to a synthetic long peptide cancer vaccine against HPV16: a phase I toxicity-immunogenicity study in cervical cancer patients.” Poster presented at ECCO-ESMO, September 2013

van Poelgeest MI, et al., Melief CJ, Kenter GG, van der Burg SH. “HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.J Transl Med. 2013 Apr 4;11:88

van der Burg SH, Melief CJ. “Therapeutic vaccination against human papilloma virus induced malignancies.” Curr Opin Immunol. 2011 Apr;23(2):252-7

Welters MJ, et al., Melief CJ, van der Burg SH. “Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9

Kenter GG, et al., Melief CJ. “Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.N Engl J Med. 2009 Nov 5;361(19):1838-47

Welters MJ, et al., Melief CJ, van der Burg SH. “Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.Clin Cancer Res. 2008 Jan 1;14(1):178-87

Kenter GG, et al., Melief CJ. “Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.Clin Cancer Res. 2008 Jan 1;14(1):169-77